Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page
- CheckyesterdayChange DetectedThe page's Revision tag was updated from v3.6.6 to v3.7.0, indicating an updated version in the site metadata.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page's revision label was updated from v3.6.5 to v3.6.6. This reflects a minor update to the page's revision metadata rather than substantive content changes.SummaryDifference0.1%

- Check36 days agoChange DetectedThe page's revision label was updated from v3.6.4 to v3.6.5. This indicates a new version of the site.SummaryDifference0.0%

- Check50 days agoChange DetectedThe page footer now includes a new Revision: v3.6.4 tag, replacing the previous Revision: v3.6.3 tag, signaling the latest page revision.SummaryDifference0.0%

- Check79 days agoChange DetectedThe revision label on the page was updated to v3.6.3, indicating a newer build of the site.SummaryDifference0.0%

- Check93 days agoChange DetectedAdded recruitment notice 'No longer looking for participants' and new help/navigation sections including How to Read a Study Record, Common Questions, How to Join a Study, and an updated Intervention/Treatment heading. Old heading 'Intervention / Treatment' and the previous revision label 'v3.5.5' were removed and replaced with the current revision 'v3.6.0'.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.